The Broker Opportunity in the Cost Crunch Rising employee benefits costs are a headache for employers
Lilly has been investing aggressively, but the company has had supply constraints on tirzepatide that compounding pharmacies stepped into
Heo J, Lim J, Lee S, Jeong J, Kang H, Kim Y, et al
[17] [18] This risk has not been fully characterised for retatrutide specifically
Read on to learn more about the key differences between Contrave and Wegovy, including their mechanism of action, side effects, and expected weight loss
Importantly, the association was more pronounced in patients with obesity/overweight, indicating a potential protective effect against CRC that may be partly driven by weight loss, as well as other mechanisms unrelated to weight loss